Health insurance stocks: UnitedHealth Group, CVS, and Humana are rising on Medicare Advantage news
Health insurance stocks, including those of UnitedHealth Group, Humana, and CVS Health, are increasing after the Trump administration decided to significantly raise Medicare insurer payments. This decision backtracks on an earlier, lower increase proposal and follows extensive lobbying from the private insurance industry. The revised plan means an additional $13 billion will be paid to private health insurers for Medicare Advantage in 2027, with a net average increase of 2.48%.
S&P 500 Futures Decline in Premarket Trading; Valmont Industries, Loews Lag
S&P 500 futures are declining in premarket trading, with specific companies like Valmont Industries and Loews lagging. Conversely, Humana Inc. (HUM) and Brookfield Wealth Solutions Ltd. (BNT) are showing significant gains, up 9.8% and 9.7% respectively, as the U.S. stock markets approach their open. This article provides an early look at market movements before trading begins.
Centene Corp. stock: Why it's drawing investor attention amid healthcare shifts
Centene Corp. is gaining investor attention due to a 4% stock increase following a rise in Medicare Advantage rates for 2027, signaling brighter prospects for the managed care giant. The article details Centene's business model focused on government-funded healthcare programs like Medicaid and Medicare, its competitive advantages in a fragmented market, and risks including regulatory changes and competition. Analysts hold a cautious "Hold" rating with potential upside, making it a defensive play for long-term investors.
Daytona Street Capital LLC Invests $2.69 Million in CVS Health Corporation $CVS
Daytona Street Capital LLC has acquired a new position of 33,888 shares in CVS Health Corporation, valued at approximately $2.69 million, making it their 16th largest holding. This investment comes as CVS reported strong Q4 results, exceeding EPS and revenue estimates, and announced a quarterly dividend of $0.665. Analysts maintain a "Moderate Buy" rating for CVS with an average target price of $94.95.
Insurance stocks jump on Medicare Advantage rate boost: Humana, UnitedHealth, lead gains (UNH:NYSE)
Insurance stocks, including Humana and UnitedHealth, saw increases after the Centers for Medicare & Medicaid Services (CMS) announced a 2.48% boost in average Medicare Advantage payments for 2027, totaling over $13 billion. This positive news led to gains for major insurance companies in after-hours trading.
CVS Pharmacy: Essential Retail for Health and Wellness Needs
CVS Pharmacy is an essential retail healthcare provider offering a wide range of prescription drugs, over-the-counter medications, health products, and convenience items. It integrates healthcare into daily shopping routines, providing accessibility, affordability, and critical support for chronic disease management and wellness. The company leverages technology, stringent quality standards, and digital engagement to maintain its market position against competitors and global influences.
New Medicare Payment Rate Released. Why UnitedHealth Stock Is Popping.
The federal government has announced a 2.48% average increase in Medicare payments to insurers for next year, a significant financial update for major health insurance companies. This news has led to a rise in UnitedHealth's stock. Medicare Advantage is a crucial business segment for these insurers, covering 35 million beneficiaries.
UnitedHealth, Humana, Health Insurers Jump On Higher Medicare Advantage Payments
UnitedHealth Group, Humana, and CVS Health saw their stock prices rise following an announcement by the Trump administration regarding higher-than-expected Medicare Advantage payment rates for 2027. The Centers for Medicare and Medicaid Services stated that rates would increase by 2.48%, totaling $13 billion, moving significantly upward from the proposed 0.09% gain announced in January. This positive adjustment in payment rates led to a jump in shares for these health insurers.
CVS, UnitedHealth, Humana, Elevance Shares Surge: Here's Why
Shares of several major health insurers, including CVS, UnitedHealth, Humana, and Elevance, saw significant after-hours gains on Monday. This surge followed the Centers for Medicare and Medicaid Services (CMS) finalizing payment policies for 2027, projecting a net average increase of 2.48% for Medicare Advantage (MA) and Part D plans. The CMS stated that these updates aim to keep coverage affordable and ensure value for patients.
April 2026 Regulatory & Legislative Update
This April 2026 regulatory and legislative update covers several key issues impacting businesses and employees. It details a federal court decision allowing an ERISA class action case against JPMorgan Chase to proceed, highlights the importance of clear beneficiary designation procedures following a significant court ruling, and clarifies the DOL's reinstatement of the "Five-Part Test" for investment advice fiduciaries. Additionally, the article addresses the "GLP-1 dilemma" for health plans regarding high-cost medications and outlines new Washington PFML premium adjustments and forthcoming paid sick and family leave bills in Virginia.
May 6 webcast: CVS Health to detail first-quarter 2026 results
CVS Health (NYSE: CVS) announced it will hold its first-quarter 2026 earnings conference call on Wednesday, May 6, 2026, at 8:00 a.m. ET. An audio webcast will be available live and archived for one year on the company's investor relations website. Historically, similar pre-announcements have resulted in modest stock price movements of around 0.37%.
SteelPeak Wealth LLC Trims Stake in CVS Health Corporation $CVS
SteelPeak Wealth LLC significantly reduced its holdings in CVS Health Corporation by 95.9% in the fourth quarter of 2025, selling 117,739 shares and retaining 5,057 shares worth $401,000. Despite this, CVS Health reported strong quarterly earnings, surpassing analyst expectations with $1.09 EPS and $105.69 billion in revenue, and declared a quarterly dividend of $0.665. The company maintains an average analyst rating of "Moderate Buy" with a consensus target price of $94.95.
What restaurants are open on Easter Sunday? What about stores?
This article provides a comprehensive list of restaurants and stores that will be open or closed on Easter Sunday, April 5, 2026. It details the operating hours for major retailers like Walmart, Costco, and Whole Foods, as well as popular food establishments such as McDonald's, Starbucks, and Chick-fil-A, to help individuals plan their holiday activities.
CVS Pharmacy: Essential Retail for Health and Wellness Needs
CVS Pharmacy serves as a crucial retail healthcare provider, offering a wide array of prescription medications, over-the-counter products, and health services globally through both physical stores and digital platforms. It integrates technology for efficiency, emphasizes product quality and variety, and maintains strict regulatory compliance. Operating under CVS Health Corporation, CVS Pharmacy is expanding its services with health hubs and personalized medicine, aiming to adapt to evolving consumer needs and market trends.
Target opens massive new West Orange location with 280 jobs
A new 150,000-square-foot Target store recently opened in West Orange Plaza, creating approximately 280 jobs and expanding shopping options for the Essex County community. This is Target's 55th location in New Jersey and includes features such as drive-up service, a CVS pharmacy, and a Starbucks cafe. The opening is part of a larger redevelopment effort by Levin Management Corp. at the plaza.
CVS HEALTH Corp ($CVS) CEO 2025 Pay Revealed
This article reveals the anticipated compensation for the CEO of CVS Health Corp ($CVS) in 2025. This information is often of interest to investors and financial analysts as executive pay can be a point of discussion regarding corporate governance and financial performance. The exact figures and breakdown of the compensation package would be detailed within the article.
Toth Financial Advisory Corp Boosts Stock Position in CVS Health Corporation $CVS
Toth Financial Advisory Corp significantly increased its stake in CVS Health Corporation by 24.8%, now holding 89,591 shares valued at $7.11 million. This increase comes as CVS Health recently exceeded quarterly earnings expectations with $1.09 EPS and reported strong revenue growth, alongside declaring a quarterly dividend of $0.665. The company maintains a "Moderate Buy" rating from analysts with an average target price of $94.95, reflecting confidence in its performance and future outlook despite a high dividend payout ratio.
CVS Health Corporation (CVS) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of CVS Health Corporation (CVS) stock, including its current price, recent news headlines, and performance data. It highlights the stock's trading activity, recent developments like the proposed FTC settlement on insulin pricing, and analyst coverage. The page also presents a performance overview comparing CVS's returns against the S&P 500.
Form DEFA14A CVS HEALTH Corp
CVS Health Corporation has filed a DEFA14A form with the SEC to announce details for its 2026 Annual Meeting of Stockholders, scheduled for May 14, 2026. The filing outlines important voting items including the election of directors, ratification of their independent registered public accounting firm, an advisory vote on executive compensation, and a proposal for their 2026 Incentive Compensation Plan. Stockholders are also being asked to vote on a shareholder proposal regarding reducing the threshold for the right to act by written consent, which the board recommends against.
[ARS] CVS HEALTH Corp SEC Filing
This article announces an ARS SEC filing by CVS Health Corp on April 3, 2026, which is available as a PDF document. It provides a brief overview of the filing's low impact and neutral sentiment. The article also includes various stock data for CVS, such as market cap and industry, along with recent news and other SEC filings related to the company.
CVS class action alleges kickbacks for drug formulary access
A new class action lawsuit has been filed against CVS Health Corp. and its pharmacy benefit manager (PBM) CaremarkPCS Health LLC, alleging that the companies sold access to their drug formularies in exchange for kickbacks from drug manufacturers. The plaintiff, Roofers’ Unions Welfare Trust Fund, claims that CVS and Caremark manipulated formularies to favor high-cost drugs over cheaper equivalents, driving up prescription drug costs for their PBM customers. The lawsuit seeks to represent all entities nationwide affected by this alleged fraudulent scheme since March 18, 2020.
CVS class action alleges kickbacks for drug formulary access
A class action lawsuit has been filed against CVS Health Corp. and its PBM CaremarkPCS Health LLC, alleging they sold access to drug formularies to manufacturers in exchange for kickbacks. The plaintiff, Roofers’ Unions Welfare Trust Fund, claims this scheme drove up drug costs for PBM customers by prioritizing high-cost drugs and diverting payments to a CVS subsidiary rather than securing greater rebates. The lawsuit seeks to represent all entities that incurred inflated costs due to this alleged fraudulent scheme since March 18, 2020.
⚠️ HEALTH WARNING: The recall includes products sold at major retailers like Walgreens and CVS.
A health warning has been issued regarding a recall of over 3 million bottles of eye drops. The recalled products were sold under various brands and at major retailers including Walgreens, CVS, Meijer, H-E-B, Kroger, and Rite Aid. Consumers are advised to check if they have any of the affected eye drops.
Dorato Capital Management Makes New Investment in Schwab U.S. Aggregate Bond ETF $SCHZ
Dorato Capital Management has made a new investment in Schwab U.S. Aggregate Bond ETF ($SCHZ), purchasing 83,801 shares valued at approximately $1,968,000, making it their 14th biggest holding. Other hedge funds have also adjusted their positions in SCHZ. The ETF recently paid a monthly dividend of $0.0772, representing an annualized dividend yield of 4.0%.
Aberdeen Group plc Lowers Stake in CVS Health Corporation $CVS
Aberdeen Group plc reduced its stake in CVS Health Corporation by 2.7% during the fourth quarter of 2025, selling 46,103 shares and retaining 1,645,029 shares valued at approximately $130.55 million. This divestment occurred as CVS Health reported strong Q4 earnings, beating analyst expectations with $1.09 EPS on $105.69 billion revenue, and declared a quarterly dividend of $0.665 per share. Analysts generally maintain a "Moderate Buy" rating for CVS, with a consensus price target of $94.95, even as the company focuses on expanding health services and faces some regulatory scrutiny.
CVS Pharmacy's Strategic Expansion in Digital Health and Retail Pharmacy Services Drives Long-Term Investor Value in North America
CVS Pharmacy is strategically expanding its digital health and retail pharmacy services, integrating innovative digital tools and MinuteClinics, to position itself as a resilient investment choice in North America's evolving healthcare market. The company focuses on convenience, affordability, and preventive care, leveraging its extensive network and digital transformation to enhance accessible healthcare for consumers. These efforts, alongside efficient supply chains and pricing strategies, aim to drive long-term investor value in a volatile market.
CVS Health Corp. stock outperforms competitors on strong trading day
Shares of CVS Health Corp. (CVS) rose 1.38% to $73.49 on Thursday, marking its fourth consecutive day of gains. This performance occurred on a mixed trading day where the S&P 500 Index (SPX) increased slightly and the Dow Jones Industrial Average (DJIA) saw a minor decline.
[Form 4] CVS HEALTH Corp Insider Trading Activity
CVS Health executive Steven H. Nelson, EVP and President of Aetna, reported equity compensation including a grant of 143,712 stock options at an exercise price of $71.82 and 22,277 restricted shares. These awards, exercisable and lapsing in installments starting March 31, 2027, involved surrendering 2,432 shares to cover tax withholdings. Following these transactions, Nelson holds 2,900 common shares and 43,606 restricted shares directly, along with 143,712 stock options.
CVS Health (NYSE: CVS) grants options and RSUs to top legal executive
CVS Health's EVP, CPO, and General Counsel, Samrat S. Khichi, received equity compensation, including 80,838 stock options and 12,531 restricted stock units, and surrendered 3,541 shares to cover withholding taxes. The stock options are exercisable in three annual installments starting March 31, 2027, and expire in 2036, while RSU restrictions also lapse in three installments from March 31, 2027. Following these transactions, Khichi holds 33,421 direct common shares.
CVS Health (CVS) grants options and RSUs to EVP Prem Shah
CVS Health EVP Prem S. Shah received significant equity compensation, including 161,676 stock options with an exercise price of $71.82 and 25,062 restricted common shares. These awards, granted on March 31, 2026, are part of the company’s 2017 Incentive Compensation Plan, with vesting periods beginning March 31, 2027. Additionally, Shah surrendered 1,484 common shares to cover tax withholdings related to the vesting of restricted stock units.
CVS Pharmacy's Digital Health Innovations Drive Strategic Growth in North American Retail Pharmacy S
CVS Pharmacy is solidifying its leadership in the North American retail pharmacy sector through extensive digital health innovations, including telehealth expansions, AI-driven personalization, and integrated MinuteClinic services. These strategic moves, combined with a focus on generics, biosimilars, and strong clinical services, are designed to meet evolving consumer demands for convenient and affordable healthcare. For investors, CVS Health (US1266501006) presents a strong value proposition with resilient revenue streams, predictable cash flows, and defensive growth potential in the healthcare essentials market.
CVS Pharmacy's Digital Health Innovations Drive Strategic Growth in North American Retail Pharmacy S
CVS Pharmacy is solidifying its leadership in the North American retail pharmacy sector through significant digital health innovations and expanded clinical services, including enhanced app-based prescription management, MinuteClinic virtual care, and AI integration. These strategic moves position CVS for continued growth by meeting evolving consumer demands for convenient and affordable healthcare. The company's resilience, driven by integrated care models and robust market share gains, makes it an attractive option for investors seeking stable revenue streams in the healthcare sector.
Cigna posts Q1 results by 6:30 a.m. ET, holds investor call April 30
The Cigna Group (NYSE: CI) announced it will release its first quarter 2026 financial results on April 30, 2026, by 6:30 a.m. ET. Management will host a conference call to discuss these results at 8:30 a.m. ET, with a live webcast and replay available. This announcement continues the company's established practice of pre-announcing earnings logistics, with historical data showing an average -5.52% stock move following previous earnings-tagged events, despite often positive fundamentals.
Healthcare Services Group Stock: A Deep Dive into Business Model, Market Position, and Investor Cons
This article provides a detailed analysis of Healthcare Services Group (HCSG), a key player in outsourced services for healthcare facilities. It examines HCSG's stable business model focused on housekeeping and dietary services for long-term care, its strong market position due to specialized expertise in an aging population, and its conservative financial health. The analysis also addresses investor considerations for North American portfolios, highlighting the stock's defensive nature and dividend appeal, alongside potential risks like labor costs and regulatory changes.
Larry Robbins Increases Stake in DXC Technology Co
Larry Robbins, through Glenview Capital Management, increased his stake in DXC Technology Co (DXC) by acquiring an additional 579,528 shares at $11.90 each on March 20, 2026. This transaction represents a 5.20% portfolio impact and increases Glenview's total holdings to 8,895,875 shares, indicating Robbins' confidence despite DXC's "Possible Value Trap" valuation status. DXC Technology, an IT services provider, has a market cap of $2.13 billion and a current stock price of $12.54.
[144] Dyne Therapeutics, Inc. SEC Filing
This article reports on a recent SEC Form 144 filing by Dyne Therapeutics, Inc. A Form 144 indicates an intent to sell restricted securities without public registration. The filing details the proposed sale of 5,727 shares of common stock by Stifel Nicolaus & Company Inc. on April 1, 2026, which were acquired through restricted stock units as equity compensation.
TVTX (NASDAQ: TVTX) files Form 144 for 60,000-share sale
Travere Therapeutics, Inc. (NASDAQ: TVTX) has filed a Form 144, indicating an intended sale of 60,000 shares of common stock on April 1, 2026, through a cash transaction. The filing details that these shares originated from an option granted on January 31, 2020. This document also discloses several prior sales by Eric M. Dube, accounting for 8,135, 51,865, 100,087, and 60,000 shares between January 23, 2026, and February 20, 2026.
Cancer screening rates dip in US as cost concerns deter access
A new survey by the Prevent Cancer Foundation indicates that nearly three-quarters of U.S. adults are behind on routine cancer screenings, a 4% increase from the previous year. Financial strain, particularly concerns about unexpected costs and potential follow-up tests, is a major contributing factor, even though initial screenings are often covered as preventive care. Additionally, a lack of patient education, logistical barriers, and flagging trust in the healthcare industry are also hindering screening rates.
New dry eye data vs. Restasis joins Sight Sciences glaucoma studies at ASCRS
Sight Sciences (SGHT) announced that new clinical data for its OMNI Surgical System and TearCare System will be presented at the 2026 ASCRS Annual Meeting on April 11. The OMNI data reportedly show reduced long-term diurnal IOP fluctuations, while TearCare data demonstrate early and sustained superiority over Restasis for tear film stability. These presentations aim to highlight the durability and versatility of their technologies, supporting broader adoption among eyecare providers.
[144] REALTY INCOME CORP SEC Filing
This article is an SEC filing (Form 144) for Realty Income Corp (O). The filing details a proposed sale of 3,275 shares of common stock by an individual, acquired through a stock award on May 18, 2021. The aggregate market value of the shares is $202,624.25, and the sale is expected to occur on April 1, 2026, on the NYSE.
Alfred Stern gains 93.589 phantom stock units at Air Products (NYSE: APD)
Air Products & Chemicals director Alfred Stern acquired 93.589 phantom stock units on March 31, 2026, through the company's Deferred Compensation Program. This grant increases his total holdings to 1,650.4763 phantom stock units, which will be settled in common stock shares after his service on the Board ends. The units have a reference price of $291.56 each.
Omnicare sets sale floor as rival bids stay open until April 30
Omnicare, a subsidiary of CVS Health, has entered into an asset purchase agreement with GenieRx, which will serve as the "stalking horse bidder" in Omnicare's court-supervised sale process. This agreement establishes a floor price for the sale of Omnicare's assets, with competing bids due by April 30, 2026. An auction is anticipated on May 5, 2026, if qualified bids are received, and Omnicare will continue to serve its skilled nursing and assisted living customers throughout the process.
Systane Eye Drops: Alcon's Leading Dry Eye Relief Product Driving Steady Growth in North American Ophthalmic Market
Alcon's Systane eye drops continue to dominate the North American dry eye treatment market, driven by increasing screen time and environmental factors. The product's clinically proven formulations, strong market share, and continuous innovation contribute to reliable revenue streams for Alcon. Systane's strategic importance in the ophthalmic sector is highlighted by its consistent sales performance, strong investor confidence, and plans for future line extensions and market expansion.
Vaughan Nelson Investment Management L.P. Sells 17,250 Shares of CVS Health Corporation $CVS
Vaughan Nelson Investment Management L.P. reduced its stake in CVS Health Corporation by 50.3%, selling 17,250 shares and retaining 17,035 shares worth approximately $1.35 million. Despite this sale, analyst sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $94.95. CVS recently exceeded revenue and EPS expectations, provided optimistic FY2026 guidance, and declared a quarterly dividend of $0.665.
CVS Health Corporation $CVS Shares Acquired by Nisa Investment Advisors LLC
Nisa Investment Advisors LLC increased its stake in CVS Health Corporation by 5.7% in the fourth quarter, bringing its total holdings to 363,095 shares valued at $28.815 million. CVS Health's recent earnings beat expectations, reporting $1.09 EPS and $105.69 billion in revenue, leading to a FY2026 EPS guidance of $5.94-$6.14. The company also declared a quarterly dividend of $0.665 per share and plans to open approximately 60 new stores in 2026, though it faces potential headwinds from a proposed FTC settlement regarding insulin pricing.
Leerink sees UnitedHealth stock facing largest RADV audit exposure
Leerink's report indicates that the Centers for Medicare & Medicaid Services (CMS) is significantly expanding its 2020 Risk Adjustment Data Validation (RADV) audits, reviewing 470 Medicare Advantage contracts compared to 58 in 2018. UnitedHealth Group (NYSE:UNH) faces the most substantial exposure, with 60 contracts covering 92% of its 2020 Medicare Advantage membership under review. All publicly traded Medicare Advantage plans are included in these expanded audits, which will begin processing in April 2025.
List of 19 Acquisitions by CVS Health (Apr 2026)
CVS Health has completed 19 acquisitions, with peak activity in 2018 and 2006. The acquisitions are primarily in the United States and focus on sectors like Internet First Insurance Platforms and Clinic Chains. The most recent acquisition was Hella Health in April 2024, a platform offering Medicare health insurance plans.
CVS Health Corp (XSWX:CVS) Dividend
This article provides key financial metrics for CVS Health Corp (XSWX:CVS) including its P/E, P/B, market cap, and enterprise value. It highlights that GuruFocus detected three severe warning signs for CVS and encourages users to sign up for a free trial to investigate these warnings. The content also lists various research tools and resources available on the GuruFocus platform.
Pineal Capital Management Issues Open Letter to the Board of Teladoc Health, Inc.
Pineal Capital Management, a shareholder in Teladoc Health, has issued an open letter to the company's Board of Directors expressing concern over the undervalued stock and the slow pace of action regarding key strategic areas. The firm believes Teladoc is vulnerable to an opportunistic takeover and urges the board to implement a value-unlock plan focusing on cost efficiencies, a major share buyback program, and a strategic review including potential separation of its core businesses. Pineal Capital highlights strong near-term business tailwinds and the significant hidden value, particularly within Teladoc's mental health platform, which it believes the market currently undervalues.
FitLife Brands (NASDAQ: FTLF) adds Irwin Naturals in $42.5M debt-funded acquisition
FitLife Brands (NASDAQ: FTLF) has acquired Irwin Naturals for $42.5 million, a debt-funded acquisition that significantly expands its brand portfolio and wholesale reach. The deal, detailed in its recent 10-K filing, was primarily financed by a new term loan and revolving credit facility, leading to a substantial increase in FitLife's total debt to $44.7 million. While the acquisition drives revenue growth, it also highlights FitLife's high reliance on Amazon and key wholesale partners, with 49% of 2025 sales through Amazon and 14% via GNC.
